All AbMole products are for research use only, cannot be used for human consumption.
A-83-01, an inhibitor of TGF-β type I receptor, increased the expression of Myf5 and MyoD, and enhanced myotube formation.The targeting efficacy of single intravenous injections of F-SL combined with A-83-01 was evaluated by measurement of the biodistribution and the antitumor effect in mice bearing murine lung carcinoma M109. A-83-01 temporarily changed the tumor vasculature around 3 h post injection. A-83-01 induced 1.7-fold higher compound accumulation of F-SL in the tumor than liposome alone at 24 h post injection.
*The compound is unstable in solutions, freshly prepared is recommended
Cancer Cell. 2024 Apr 8;42(4):535-551.e8.
Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer
A 83-01 purchased from AbMole
Cancer Lett. 2024 Oct 02;605:217284.
Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer
A 83-01 purchased from AbMole
Cell Death Dis. 2024 Oct 15;15(10):749.
USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression
A 83-01 purchased from AbMole
Biochim Biophys Acta Gen Subj. 2024 Jan;1868(4):130566.
Gastric cancer patient-derived organoids model for the therapeutic drug screening
A 83-01 purchased from AbMole
Adv Sci (Weinh). 2023 Jul 23;e2302640.
Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients
A 83-01 purchased from AbMole
Cell Death Dis. 2022 Apr 5;13(4):303.
KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response
A 83-01 purchased from AbMole
Nat Biomed Eng. 2020 Sep;4(9):863-874.
High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays
A 83-01 purchased from AbMole
 |
Source | Breast Cancer Res Treat (2017). Figure 6. A 83-01 |
| Method | MTT assay | |
| Cell Lines | SKBR3 cells | |
| Concentrations | 1 μM | |
| Incubation Time | 16 h | |
| Results | As shown in Fig. 6c that A83-01 alone reduced approximately 17% cell migration of JIMT1 and trastuzumab alone inhibited 20% cell migration, while in combination of A83-01 and trastuzumab synergistically inhibited JIMT1 cell migration up to 90%. |
| Molecular Weight | 421.52 |
| Formula | C25H19N5S |
| CAS Number | 909910-43-6 |
| Solubility (25°C) | DMSO 24 mg/mL |
| Storage | -20°C, protect from light, dry, sealed |
| Related TGF-β Receptor Products |
|---|
| CJJ300
CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 µM. |
| AZ12601011
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. |
| TGF-βRI inhibitor 1
TGF-βRI inhibitor 1 (compoimd i) is a TGF-βRI inhibitor. |
| TGF-βRI inhibitor 1 methylbenzenesulfonate
TGF-βRI inhibitor 1 (compoimd i) methylbenzenesulfonate is a TGF-βRI inhibitor. |
| LSKL TFA
LSKL TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
